salicylic acid has been researched along with Depressive Disorder in 8 studies
Scalp: The outer covering of the calvaria. It is composed of several layers: SKIN; subcutaneous connective tissue; the occipitofrontal muscle which includes the tendinous galea aponeurotica; loose connective tissue; and the pericranium (the PERIOSTEUM of the SKULL).
Depressive Disorder: An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The rates of androgenetic alopecia and telogen effluvium were 26." | 1.35 | The role of psychological factors and serum zinc, folate and vitamin B12 levels in the aetiology of trichodynia: a case-control study. ( Adiguzel, A; Arikan, S; Budakoglu, IY; Durusoy, C; Gulec, AT; Ozenli, Y; Tugal, O; Uslu, A, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| VONWEISS, JF | 1 |
| LEVER, WF | 1 |
| Durusoy, C | 1 |
| Ozenli, Y | 1 |
| Adiguzel, A | 1 |
| Budakoglu, IY | 1 |
| Tugal, O | 1 |
| Arikan, S | 1 |
| Uslu, A | 1 |
| Gulec, AT | 1 |
| van den Hurk, CJ | 1 |
| Mols, F | 1 |
| Vingerhoets, AJ | 1 |
| Breed, WP | 1 |
| Kozian, R | 1 |
| Mowlavi, A | 1 |
| Bass, MJ | 1 |
| Khurshid, KA | 1 |
| Milner, S | 1 |
| Zook, EG | 1 |
| Huang, Y | 1 |
| Li, DJ | 1 |
| Tang, AW | 1 |
| Li, QS | 1 |
| Xia, DB | 1 |
| Xie, YN | 1 |
| Gong, W | 1 |
| Chen, J | 1 |
| Rácz, E | 1 |
| Kornseé, Z | 1 |
| Csikós, M | 1 |
| Dobos, M | 1 |
| Salacz, P | 1 |
| Kárpáti, S | 1 |
| George, MS | 1 |
| Nahas, Z | 1 |
| Kozel, FA | 1 |
| Goldman, J | 1 |
| Molloy, M | 1 |
| Oliver, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Therapeutic Efficacy of Cerebellar Repetitive Transcranial Magnetic Stimulation in Patients With Schizophrenia[NCT01551979] | 22 participants (Actual) | Interventional | 2012-02-29 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Calgary Depression Scale for Schizophrenia is a 9-item scale that assesses depressive symptoms in patients with schizophrenia. Each item is rated separately and ratings range from 0 to 3. Higher values represent more severe depressive symptoms: 0 indicates an absent symptom and 3 indicates a severe symptom. The overall Calgary Depression Scale score is computed by summing each item. The total Calgary Depression Scale score ranges from 0 to 27, with higher values representing more severe depression in patients with schizophrenia. Change from baseline on the Calgary Depression Scale can range from -27 to +27, with negative values representing an improvement in depressive symptoms and positive values representing worsening depressive symptom severity. Depression was assessed at baseline, after 5 days of treatment, 1 week post treatment, and 3 weeks post treatment. (NCT01551979)
Timeframe: Before treatment (baseline), last day of treatment (after 5 days of treatment), 1 and 3 weeks post treatment
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| 5 days of treatment - baseline | 1 week post treatment - baseline | 3 week post treatment - baseline | |
| Active rTMS | -2.6 | -2.7 | -2.25 |
| Sham rTMS | -1.167 | -1.833 | 0.8 |
Treatment response was evaluated with the Clinical Global Impressions (CGI) Scale, which is comprised of two companion one-item measures that use 7-point scales to evaluate severity of psychopathology and improvement from the initiation of treatment; each component is rated separately and the CGI does not yield a global score. The CGI Severity of Illness is a 7-point subscale in which a clinician rates the severity of the patient's illness at the time of assessment. Ratings range from 1 to 7 and higher values represent more severe psychopathology: 1 indicates a normal and not at all ill patient and 7 indicates among the most extremely ill patients. Change from baseline on the CGI Severity of Illness subscale can range from -6 to +6, with negative values representing an improvement in psychopathology and positive values representing worsening psychopathology. Severity of Illness was assessed at baseline, after 5 days of treatment, 1 week post treatment, and 3 weeks post treatment. (NCT01551979)
Timeframe: Before treatment (baseline), last day of treatment (after 5 days of treatment), 1 and 3 weeks post treatment
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| 5 days of treatment - baseline | 1 week post treatment - baseline | 3 week post treatment - baseline | |
| Active rTMS | -0.3 | -0.4 | -0.5 |
| Sham rTMS | -0.286 | -0.5 | -0.2 |
Therapeutic efficacy was evaluated with the Positive and Negative Syndrome Scale (PANSS) General Subscale, a 16 item subscale measuring the presence/absence and severity of general psychopathology of schizophrenia. The minimum score is 16 and the maximum score is 112, with higher values representing greater psychopathology severity. Change from baseline on the PANSS General Subscale can range from -96 to +96; negative values represent an improvement in symptom severity, and positive values represent worsening symptom severity. Therapeutic efficacy was assessed at baseline, after 5 days of treatment, 1 week post treatment, and 3 weeks post treatment. (NCT01551979)
Timeframe: Before treatment (baseline), last day of treatment (after 5 days of treatment), 1 and 3 weeks post treatment
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| 5 days of treatment - baseline | 1 week post treatment - baseline | 3 week post treatment - baseline | |
| Active rTMS | -3.1 | -8.222 | -7.375 |
| Sham rTMS | -2.714 | -2 | 0 |
Therapeutic efficacy was evaluated with the Positive and Negative Syndrome Scale (PANSS) Negative Subscale, a 7 item subscale measuring the presence/absence and severity of negative symptoms of schizophrenia. The minimum score is 7 and the maximum score is 49, with higher values representing greater symptom severity. Change from baseline on the PANSS Negative Subscale can range from -42 to +42; negative values represent an improvement in symptom severity, and positive values represent worsening symptom severity. Therapeutic efficacy was assessed at baseline, after 5 days of treatment, 1 week post treatment, and 3 weeks post treatment. (NCT01551979)
Timeframe: Before treatment (baseline), last day of treatment (after 5 days of treatment), 1 and 3 weeks post treatment
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| 5 days of treatment - baseline | 1 week post treatment - baseline | 3 week post treatment - baseline | |
| Active rTMS | -1 | -3.889 | -3.5 |
| Sham rTMS | -1.571 | -1.667 | -0.2 |
Therapeutic efficacy was evaluated with the Positive and Negative Syndrome Scale (PANSS) Positive Subscale, a 7 item subscale measuring the presence/absence and severity of positive symptoms of schizophrenia. The minimum score is 7 and the maximum score is 49, with higher values representing greater symptom severity. Change from baseline on the PANSS Positive Subscale can range from -42 to +42; negative values represent an improvement in symptom severity, and positive values represent worsening symptom severity. Therapeutic efficacy was assessed at baseline, after 5 days of treatment, 1 week post treatment, and 3 weeks post treatment. (NCT01551979)
Timeframe: Before treatment (baseline), last day of treatment (after 5 days of treatment), 1 and 3 weeks post treatment
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| 5 days of treatment - baseline | 1 week post treatment - baseline | 3 week post treatment - baseline | |
| Active rTMS | -2.4 | -5.889 | -5 |
| Sham rTMS | -1.857 | -3.667 | -3 |
Treatment response was evaluated with the Clinical Global Impressions (CGI) Scale, which is comprised of two companion one-item measures that use 7-point scales to evaluate severity of psychopathology and improvement from the initiation of treatment; each component is rated separately and the CGI does not yield a global score. The CGI Global Improvement is a 7-point subscale in which a clinician assesses how much a patient's illness has changed compared to baseline. Ratings range from 1 to 7, with 1 indicating very much improved and 7 indicating very much worse. Change from baseline on the CGI Global Improvement subscale can range from -6 to +6, with negative values representing an improvement in psychopathology and positive values representing worsening psychopathology. Global Improvement was assessed after 5 days of treatment, 1 week post treatment, and 3 weeks post treatment. (NCT01551979)
Timeframe: Last day of treatment (after 5 days of treatment), 1 and 3 weeks post treatment
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| 5 days of treatment | 1 week post treatment | 3 week post treatment | |
| Active rTMS | 3.6 | 3.3 | 3.375 |
| Sham rTMS | 3.429 | 4 | 3.8 |
1 review available for salicylic acid and Depressive Disorder
| Article | Year |
|---|---|
Improvement of depression following transcranial magnetic stimulation.
Topics: Cerebral Cortex; Depressive Disorder; Electric Stimulation Therapy; Humans; Neurons; Scalp; Transcra | 1999 |
1 trial available for salicylic acid and Depressive Disorder
| Article | Year |
|---|---|
Impact of alopecia and scalp cooling on the well-being of breast cancer patients.
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Anxiety Disorders; Body Image; Breast Neop | 2010 |
6 other studies available for salicylic acid and Depressive Disorder
| Article | Year |
|---|---|
PERCUTANEOUS SALICYLIC ACID INTOXICATION IN PSORIASIS.
Topics: Blood Chemical Analysis; Depression; Depressive Disorder; Diarrhea; Drug Therapy; Fluocinolone Aceto | 1964 |
The role of psychological factors and serum zinc, folate and vitamin B12 levels in the aetiology of trichodynia: a case-control study.
Topics: Adolescent; Adult; Aged; Alopecia; Case-Control Studies; Depressive Disorder; Female; Folic Acid; Hu | 2009 |
[Olanzapine in therapy of a somatoform disorder].
Topics: Antipsychotic Agents; Benzodiazepines; Chest Pain; Clomipramine; Depressive Disorder; Dose-Response | 2003 |
Psychological sequelae of failed scalp replantation.
Topics: Adult; Anxiety Disorders; Child; Depressive Disorder; Female; Humans; Male; Mental Disorders; Replan | 2004 |
[Effect of scalp acupuncture on glucose metabolism in brain of patients with depression].
Topics: Adult; Aged; Brain; Depressive Disorder; Electroacupuncture; Female; Glucose; Humans; Male; Middle A | 2005 |
Darier's disease associated with cutis verticis gyrata, hyperprolactinaemia and depressive disorder.
Topics: Calcium-Transporting ATPases; Codon, Nonsense; Darier Disease; Depressive Disorder; Female; Humans; | 2006 |